Michael Floyd - 31 Dec 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Operating Officer
Signature
/s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
31 Dec 2022
Transactions value $
$0
Form type
4
Filing time
04 Jan 2023, 16:43:27 UTC
Previous filing
11 Oct 2022
Next filing
10 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +10,851 +3.25% $0 344,531 31 Dec 2022 Common Stock 10,851 $0 Direct F1
transaction PCSA Restricted Stock Units Award $0 +55,107 +15.99% $0 399,638 01 Jan 2023 Common Stock 55,107 $0 Direct F2
transaction PCSA Restricted Stock Units Award $0 +40,690 +10.18% $0 440,328 01 Jan 2023 Common Stock 40,690 $0 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment? the third anniversary of the award date? a change of control? or the reporting person's death. These restricted stock units vest on date of grant.
F2 Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death,
F3 Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death.